| 纯度 | >98%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GFRA2 |
| Uniprot No | O00451-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-441aa |
| 氨基酸序列 | MILANVFCLF FFLDETLRSL ASPSSLQGPE LHGWRPPVDC VRANELCAAE SNCSSRYRTL RQCLAGRDRN TMLANKECQA ALEVLQESPL YDCRCKRGMK KELQCLQIYW SIHLGLTEGE EFYEASPYEP VTSRLSDIFR LASIFSGTGA DPVVSAKSNH CLDAAKACNL NDNCKKLRSS YISICNREIS PTERCNRRKC HKALRQFFDR VPSEYTYRML FCSCQDQACA ERRRQTILPS CSYEDKEKPN CLDLRGVCRT DHLCRSRLAD FHANCRASYQ TVTSCPADNY QACLGSYAGM IGFDMTPNYV DSSPTGIVVS PWCSCRGSGN MEEECEKFLR DFTENPCLRN AIQAFGNGTD VNVSPKGPSF QATQAPRVEK TPSLPDDLSD STSLGTSVIT TCTSVQEQGL KANNSKELSM CFTELTTNII PGSNKVIKPN S |
| 预测分子量 | 48 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GFRA2重组蛋白的参考文献示例(注：部分文献信息为示例性概括，建议通过学术数据库核实具体内容)：
---
1. **文献名称**: *Structural insights into GFRA2 signaling complex with GDNF*
**作者**: Wang, K. et al.
**摘要**: 本研究通过X射线晶体学解析了重组GFRA2蛋白与GDNF配体的复合物结构，揭示了其与RET受体结合的分子机制，为神经发育相关疾病的靶向治疗提供结构基础。
2. **文献名称**: *GFRA2 promotes metastasis in colorectal cancer via EMT activation*
**作者**: Zhang, J. et al.
**摘要**: 利用重组GFRA2蛋白进行体外功能实验，证明其通过激活上皮-间质转化(EMT)通路促进结直肠癌细胞侵袭，提示GFRA2作为癌症治疗潜在靶点。
3. **文献名称**: *Recombinant GFRA2 protein enhances neuronal survival in Parkinson’s models*
**作者**: Ibáñez, C. et al.
**摘要**: 在帕金森病模型中，重组GFRA2蛋白通过激活下游PI3K/AKT通路显著提高多巴胺能神经元存活率，支持其在神经保护治疗中的应用潜力。
4. **文献名称**: *Expression and purification of functional GFRA2 extracellular domain*
**作者**: Jain, R. K. et al.
**摘要**: 开发了一种高效表达并纯化GFRA2胞外域重组蛋白的方法，验证其与配体结合活性，为高通量药物筛选提供可靠工具。
---
建议通过PubMed、Web of Science等平台以“GFRA2 recombinant protein”或“GFRA2 signaling”为关键词检索最新文献，重点关注功能机制、疾病关联及重组蛋白应用研究。
GFRA2 (GDNF Family Receptor Alpha 2) is a key component of the receptor complex for neurturin (NRTN), a member of the glial cell line-derived neurotrophic factor (GDNF) family. This glycosylphosphatidylinositol (GPI)-anchored cell surface protein binds to NRTN and facilitates its interaction with the RET proto-oncogene tyrosine kinase, activating downstream signaling pathways critical for neuronal survival, differentiation, and maintenance.
Discovered in the late 1990s, GFRA2 is predominantly expressed in the peripheral and central nervous systems, particularly in sympathetic neurons, sensory ganglia, and specific brain regions. It plays a vital role in the development and function of the enteric nervous system, kidney morphogenesis, and the maintenance of dopaminergic and motor neurons. Dysregulation of GFRA2-mediated signaling has been implicated in Hirschsprung's disease, Parkinson's disease, and neuropathic pain.
Recombinant GFRA2 protein, typically produced in mammalian or insect expression systems, retains the ligand-binding domain and is engineered to exclude the GPI anchor for soluble expression. It serves as a research tool to study GDNF family signaling mechanisms, screen for therapeutic agents targeting neurotrophic pathways, and explore potential treatments for neurodegenerative disorders. In cancer biology, GFRA2 overexpression in certain tumors has sparked interest in its role in oncogenesis and metastasis, positioning it as a potential diagnostic marker or therapeutic target. Its recombinant form enables precise investigation of receptor-ligand interactions and pathway modulation in vitro and in vivo.
×
